Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Availability:

  • Sort by:
  • Browse by:
<< first | < prev page: of 12 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 9 10 11 12 presentations: 1 to 50 of 569
ORAL ABSTRACT: ADVANCES IN TB AND CRYPTOCOCCAL MENINGITIS TREATMENT AND PREVENTION
EFFECT OF TB SCREENING AND RETENTION INTERVENTIONS ON EARLY ART MORTALITY IN BOTSWANA   (ABSTRACT 31)
Andrew Francis Auld
U.S. Centers for Disease Control and Prevention (CDC), Dulles, VA, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ADVANCES IN TB AND CRYPTOCOCCAL MENINGITIS TREATMENT AND PREVENTION
A CLUSTER-RANDOMIZED TRIAL OF SYMPTOM VS TST SCREENING TO IMPROVE CHILD IPT UPTAKE   (ABSTRACT 32)
Nicole Salazar-Austin
Johns Hopkins University School of Medicine, Baltimore, MD, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ADVANCES IN TB AND CRYPTOCOCCAL MENINGITIS TREATMENT AND PREVENTION
SAFETY AND EFFICACY OF DOLUTEGRAVIR-BASED ART IN TB/HIV COINFECTED ADULTS AT WEEK 24   (ABSTRACT 33)
Kelly Dooley
Johns Hopkins University, Baltimore, MD, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ADVANCES IN TB AND CRYPTOCOCCAL MENINGITIS TREATMENT AND PREVENTION
PHARMACOKINETICS OF BICTEGRAVIR ADMINISTERED TWICE DAILY IN COMBINATION WITH RIFAMPIN   (ABSTRACT 34)
Joseph M. Custodio
Gilead Science, Foster city, CA, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ADVANCES IN TB AND CRYPTOCOCCAL MENINGITIS TREATMENT AND PREVENTION
HIGHER HIGH DOSE FLUCONAZOLE FOR THE TREATMENT OF CRYPTOCOCCAL MENINGITIS   (ABSTRACT 35)
Wadzanai Samaneka
Parirenyatwa Clinical Research Site, Harare, Zimbabwe
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ADVANCES IN TB AND CRYPTOCOCCAL MENINGITIS TREATMENT AND PREVENTION
ADJUNCTIVE SERTRALINE IN HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS   (ABSTRACT 36)
Joshua Rhein
University of Minnesota, Minneapolis, MN, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ADVANCES IN TB AND CRYPTOCOCCAL MENINGITIS TREATMENT AND PREVENTION
ONE MONTH OF RIFAPENTINE/ISONIAZID TO PREVENT TB IN PEOPLE WITH HIV: BRIEF-TB/A5279   (ABSTRACT 37LB)
Richard E. Chaisson
Johns Hopkins University, Baltimore, MD, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ADVANCES IN TB AND CRYPTOCOCCAL MENINGITIS TREATMENT AND PREVENTION
URINE-BASED SCREENING FOR TUBERCULOSIS: A RANDOMIZED TRIAL IN HIV-POSITIVE INPATIENTS   (ABSTRACT 38LB)
Ankur Gupta-Wright
London School of Hygiene & Tropical Medicine, London, United Kingdom
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ADVANCES IN TB AND CRYPTOCOCCAL MENINGITIS TREATMENT AND PREVENTION
A RANDOMIZED CONTROLLED TRIAL OF HIGH-DOSE RIFAMPIN FOR PULMONARY TUBERCULOSIS   (ABSTRACT 39LB)
Gustavo E Velásquez
Brigham and Women's Hospital, Boston, MA, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ART: NEW DATA AND NEW INSIGHTS
SWITCH TO BICTEGRAVIR/F/TAF FROM DTG AND ABC/3TC   (ABSTRACT 22)
Jean-Michel Molina
Hôpital Saint-Louis, Paris, France
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ART: NEW DATA AND NEW INSIGHTS
IMPACT OF RALTEGRAVIR INTENSIFICATION OF FIRST-LINE ART ON IRIS IN THE REALITY TRIAL   (ABSTRACT 23)
Diana Gibb
MRC Clinical Trials Unit at UCL, London, United Kingdom
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ART: NEW DATA AND NEW INSIGHTS
HAIR ANTIRETROVIRAL LEVELS STRONGLY PREDICT VIROLOGIC OUTCOMES IN ACTG'S A5257 TRIAL   (ABSTRACT 24)
Monica Gandhi
University of California San Francisco, San Francisco, CA, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ART: NEW DATA AND NEW INSIGHTS
TENOFOVIR DIPHOSPHATE IN DRIED BLOOD SPOTS IS A STRONG PREDICTOR OF VIRAL SUPPRESSION   (ABSTRACT 25)
Jose R Castillo-Mancilla
University of Colorado, Denver, Aurora, CO, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ART: NEW DATA AND NEW INSIGHTS
MULTIPLE DAILY DOSES OF MK-8591 AS LOW AS 0.25 MG ARE EXPECTED TO SUPPRESS HIV   (ABSTRACT 26)
Randolph P Matthews
Merck Research Laboratories, North Wales, PA, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ART: NEW DATA AND NEW INSIGHTS
COMPARATIVE LYMPHOID TISSUE PHARMACOKINETICS (PK) OF INTEGRASE INHIBITORS (INSTI)   (ABSTRACT 27)
Courtney V. Fletcher
University of Nebraska Medical Center, Omaha, NE, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ART: NEW DATA AND NEW INSIGHTS
RIFAMPIN EFFECT ON TENOFOVIR ALAFENAMIDE (TAF) PLASMA/INTRACELLULAR PHARMACOKINETICS   (ABSTRACT 28LB)
Maddalena Cerrone
St Stephen's Clinical Research, Chelsea and Westminster Hospital, London, UK, LONDON, United Kingdom
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ART: NEW DATA AND NEW INSIGHTS
SYSTEMATIC VS TEST-GUIDED TUBERCULOSIS TREATMENT: DATA OF THE STATIS RANDOMIZED TRIAL   (ABSTRACT 29LB)
François-Xavier Blanc
l'institut du thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, Nantes, France
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ART: NEW DATA AND NEW INSIGHTS
RESULTS OF ACTG A5288: A STRATEGY STUDY IN RLS FOR 3RD-LINE ART CANDIDATES   (ABSTRACT 30LB)
Beatriz Grinsztejn
Fiocruz, Rio de Janeiro, Brasil, Brazil
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: ART: NEW DATA AND NEW INSIGHTS
QUESTIONS AND ANSWERS
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: SURVEILLANCE AND EPIDEMIOLOGY: NEW APPROACHES
RAPIDLY GROWING HIV TRANSMISSION CLUSTERS IN THE UNITED STATES, 2013–2016   (ABSTRACT 40)
Anne Marie France
Centers for Disease Control and Prevention, Atlanta, GA, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: SURVEILLANCE AND EPIDEMIOLOGY: NEW APPROACHES
CLUSTER ANALYSIS REVEALS IMPORTANT SHIFT OF DRIVERS OF THE HIV EPIDEMIC IN SWISS MSM   (ABSTRACT 41)
Nadine Bachmann
University Hospital Zurich, Zurich, Switzerland
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: SURVEILLANCE AND EPIDEMIOLOGY: NEW APPROACHES
PHYLOGENETIC PATTERNS OF HIV TRANSMISSION AMONG TRANSGENDER WOMEN IN LOS ANGELES   (ABSTRACT 42)
Manon Ragonnet-Cronin
University of California, San Diego, San Diego, CA, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: SURVEILLANCE AND EPIDEMIOLOGY: NEW APPROACHES
ASSESSING THE ROLE OF GEOGRAPHICAL HIV HOT-SPOTS IN THE SPREAD OF THE EPIDEMIC   (ABSTRACT 43)
Diego F Cuadros
University of Cincinnati, Cincinnati, OH, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: SURVEILLANCE AND EPIDEMIOLOGY: NEW APPROACHES
USING SUCCESSIVE SURVEYS TO CALCULATE INCIDENCE AMONG AT-RISK POPULATIONS IN THE US   (ABSTRACT 44)
Janet Chuyun Burnett
Centers for Disease Control and Prevention, Atlanta, GA, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: SURVEILLANCE AND EPIDEMIOLOGY: NEW APPROACHES
FEMALE HIV ACQUISITION PER SEX ACT IS ELEVATED IN LATE PREGNANCY AND POSTPARTUM   (ABSTRACT 45)
Renee Heffron
University of Washington, Seattle, WA, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: SURVEILLANCE AND EPIDEMIOLOGY: NEW APPROACHES
SHARP DECLINE IN MALE HIV INCIDENCE IN A RURAL SOUTH AFRICAN POPULATION (2004–2015)   (ABSTRACT 46)
Alain Vandormael
University of KwaZulu-Natal, South Africa, Durban, KZN, South Africa
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: SURVEILLANCE AND EPIDEMIOLOGY: NEW APPROACHES
ONGOING HIV MICROEPIDEMICS IN RURAL SOUTH AFRICA: THE NEED FOR FLEXIBLE INTERVENTIONS   (ABSTRACT 47LB)
Cordelia Coltart
University College London, London, United Kingdom
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: VIRUS AND HOST DETERMINANTS OF HIV/SIV PATHOGENESIS
IDENTIFICATION OF A NOVEL LOCUS OF HIV REGULATION IN POPULATIONS OF AFRICAN DESCENT   (ABSTRACT 14)
Paul J McLaren
Public Health Agency of Canada, WInnipeg, Canada
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: VIRUS AND HOST DETERMINANTS OF HIV/SIV PATHOGENESIS
HOST FACTORS ASSOCIATED WITH BNAB DEVELOPMENT IN HIV-1 CONTROLLERS   (ABSTRACT 15)
Enrique Martin-Gayo
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: VIRUS AND HOST DETERMINANTS OF HIV/SIV PATHOGENESIS
INTERDOMAIN STABILIZATION IMPAIRS CD4 BINDING AND IMPROVES IMMUNOGENICITY OF SOSIPS   (ABSTRACT 16LB)
Peng Zhang
NIH, Bethesda, MD, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: VIRUS AND HOST DETERMINANTS OF HIV/SIV PATHOGENESIS
EQUAL DISTRIBUTION OF SIV DNA IN MEMORY T HELPER CELL SUBSETS OF RHESUS MACAQUES   (ABSTRACT 17)
Stephen Lai
NIH, Bethesda, MD, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: VIRUS AND HOST DETERMINANTS OF HIV/SIV PATHOGENESIS
KINETICS OF GASTROINTESTINAL DYSFUNCTION IN ACUTE SIV INFECTION OF MACAQUES   (ABSTRACT 18)
Tiffany Hensley-McBain
University of Washington, Seattle, WA, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: VIRUS AND HOST DETERMINANTS OF HIV/SIV PATHOGENESIS
PROGRESSIVE LYMPH NODE DYSFUNCTION DURING SIV INFECTION IS NOT REVERSED WITH ART   (ABSTRACT 19)
Claire Deleage
NIH, Frederick National Laboratory for Cancer Research, Frederick, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: VIRUS AND HOST DETERMINANTS OF HIV/SIV PATHOGENESIS
P38 MAPK IN VIVO INHIBITION IMPACTS SIV-MEDIATED IMMUNE ACTIVATION & CD4 T-CELL LOSS   (ABSTRACT 20)
Anna Aldovini
Boston Children's Hospital, Boston, MA, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: VIRUS AND HOST DETERMINANTS OF HIV/SIV PATHOGENESIS
INTRON−CONTAINING HIV−1 RNA ACTIVATES TYPE I INTERFERON AND INFLAMMATORY CYTOKINES   (ABSTRACT 21)
Sean McCauley
University of Massachusetts Medical School, Worcester, MA, USA
from CROI 2018 on March 5, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: 90:90:90: PROGRESS, CHALLENGES, AND NEW TOOLS
HIV TREATMENT, PREVENTION, AND INCIDENCE IN A HYPERENDEMIC UGANDAN FISHING COMMUNITY   (ABSTRACT 90)
Joseph Kagaayi
Rakai Health Science Program, Kalisizo, Uganda
from CROI 2018 on March 6, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: 90:90:90: PROGRESS, CHALLENGES, AND NEW TOOLS
PROGRESS TOWARD 90-90-90: 2016 LESOTHO POPULATION-BASED HIV IMPACT ASSESSMENT RESULTS   (ABSTRACT 91)
Kyaw Thin
Ministry of Health Lesotho, Maseru, Lesotho
from CROI 2018 on March 6, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: 90:90:90: PROGRESS, CHALLENGES, AND NEW TOOLS
CLINICAL PRESENTATION OF HIV DIFFERS BY AGE IN VACS (2010-2015)   (ABSTRACT 92)
Amy C. Justice
Veterans Administration Connecticut Healthcare System, West Haven, CT, USA
from CROI 2018 on March 6, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: 90:90:90: PROGRESS, CHALLENGES, AND NEW TOOLS
THE RAPID ART PROGRAM INITIATIVE FOR HIV DIAGNOSES (RAPID) IN SAN FRANCISCO   (ABSTRACT 93)
Oliver Bacon
San Francisco Department of Public Health, San Francisco, CA, USA
from CROI 2018 on March 6, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: 90:90:90: PROGRESS, CHALLENGES, AND NEW TOOLS
SAME-DAY ART INITIATION AFTER HOME-BASED HIV TESTING: A RANDOMIZED CONTROLLED TRIAL   (ABSTRACT 94)
Niklaus Daniel Labhardt
Swiss Tropical and Public Health Institute, Basel, Switzerland
from CROI 2018 on March 6, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: 90:90:90: PROGRESS, CHALLENGES, AND NEW TOOLS
RANDOMIZED CONTROLLED TRIAL OF FINANCIAL INCENTIVES FOR ACHIEVING VIRAL SUPPRESSION   (ABSTRACT 95)
Harsha Thirumurthy
University of Pennsylvania, Philadelphia, PA, USA
from CROI 2018 on March 6, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: 90:90:90: PROGRESS, CHALLENGES, AND NEW TOOLS
EXTENDED-RELEASE NALTREXONE IMPROVES VIRAL SUPPRESSION IN HIV+ PRISONERS   (ABSTRACT 96)
Sandra Springer
Yale School of Medicine, New Haven, CT, USA
from CROI 2018 on March 6, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: 90:90:90: PROGRESS, CHALLENGES, AND NEW TOOLS
HIGHER MORTALITY IN HIV - INFECTED VS - UNINFECTED ADULTS DESPITE ART, BOTSWANA   (ABSTRACT 97)
Tendani Gaolathe
Botswana-Harvard AIDS Institute, Gaborone, Botswana
from CROI 2018 on March 6, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: NON-AIDS COMPLICATIONS
IL-6, D-DIMER OR T-CELLS: WHICH BEST PREDICT EVENTS OR EXPLAIN BENEFITS OF EARLY ART?   (ABSTRACT 74)
Jason V Baker
HCMC / University of Minnesota, Minneapolis, MN, USA
from CROI 2018 on March 6, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: NON-AIDS COMPLICATIONS
SERIOUS CLINICAL OUTCOMES IN HIV-POSITIVE PERSONS WITH CHRONIC KIDNEY DISEASE (CKD)   (ABSTRACT 75)
Lene Ryom
CHIP, Department of Infectious Diseases, Copenhagen, Denmark
from CROI 2018 on March 6, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: NON-AIDS COMPLICATIONS
INCREASED RISK OF PERIPHERAL ARTERY DISEASE IN PERSONS WITH HIV COMPARED TO CONTROLS   (ABSTRACT 76)
Andreas Dehlbæk Knudsen
Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
from CROI 2018 on March 6, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: NON-AIDS COMPLICATIONS
HIV INFECTION IS ASSOCIATED WITH PROGRESSION OF HIGH RISK CORONARY PLAQUE IN THE MACS   (ABSTRACT 77)
Wendy Post
Johns Hopkins University, Baltimore, MD, USA
from CROI 2018 on March 6, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: NON-AIDS COMPLICATIONS
CAROTID ARTERY ATHEROSCLEROSIS IS ASSOCIATED WITH MORTALITY IN HIV+ WOMEN AND MEN   (ABSTRACT 78)
David B Hanna
Albert Einstein College of Medicine, Bronx, NY, USA
from CROI 2018 on March 6, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: NON-AIDS COMPLICATIONS
IMPACT OF LDMTX ON IMMUNE ACTIVATION AND ENDOTHELIAL FUNCTION IN TREATED HIV   (ABSTRACT 79)
Priscilla Hsue
University of California San Francisco, San Francisco, CA, USA
from CROI 2018 on March 6, 2018 10:00 AM-12:00 PM
ORAL ABSTRACT: NON-AIDS COMPLICATIONS
PLATELET FUNCTION UPON SWITCHING TO TAF VS CONTINUING ABC: A RANDOMIZED SUBSTUDY   (ABSTRACT 80)
Patrick W.G. Mallon
University College Dublin, Dublin, Ireland
from CROI 2018 on March 6, 2018 10:00 AM-12:00 PM
<< first | < prev page: of 12 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 9 10 11 12 presentations: 1 to 50 of 569